Key result
Test ticagrelor proves bioequivalent to the reference formulation in healthy adult males.
Why the study?
The study was conducted to evaluate the bioequivalence and safety profiles of a test drug versus reference drug of 90 mg ticagrelor tablets under fasting conditions.
Does the test formulation of ticagrelor 90 mg achieve bioequivalence to the reference formulation in healthy Indian adults?
RCT (n=42)
blinded
randomized
Does the test formulation of ticagrelor 90 mg achieve bioequivalence to the reference formulation in healthy Indian adults?
The test formulation of ticagrelor 90 mg is bioequivalent to the reference formulation and well-tolerated in healthy Indian adults.
Answers are grounded in this paper and cite their sources.
Supports substitution of the test ticagrelor formulation in Indian practice; extends bioequivalence data to this population.
Objectives: The objectives of this study were to evaluate the bioequivalence and safety profiles of the test drug and reference drug of 90 mg ticagrelor tablets under fasting conditions. Methods: This was a randomized, blinded, balanced, two-treatment, two-period, two-sequence, single-dose, crossover bioequivalence study in normal, healthy adults. Subjects were randomized to receive a single dose of test or reference drug (ticagrelor 90 mg oral) under fasting conditions with a 16-day washout period. The primary pharmacokinetic variables were peak plasma concentration (C max ), area under the plasma concentration (AUC) time curve measured to the last quantifiable concentration (AUC T ), and time to maximum drug concentration (T max ). Bioequivalence was concluded if 90% confidence intervals (CIs) of the geometric mean ratio of the test/reference drugs AUC T and C max are within the predefined range of 80%–125%. Adverse events (AEs) were also assessed. Results: Forty-two healthy adult males were enrolled, but 4 withdrew and 38 subjects successfully completed the study. There was no difference between the test and reference drugs regarding pharmacokinetic parameters. The median (range) T max was 1.67 h (1–4 h) and 2 h (1–4.5 h) for the test and reference products, respectively. The estimated 90% CIs of the geometric mean ratio for AUC T and C max satisfied the predefined bioequivalence criteria of 80%–125%. On analysis of variance, no significant “sequence” and “period” effects were observed for the pharmacokinetic parameters . No AEs were reported in the study. Conclusion: Our findings indicate that the test product is bioequivalent to the reference product and safe and well-tolerated in healthy Indian adults.
No takes yet. Share an insight, caveat, or question.
Pradeep et al. (2023) conducted an RCT in Healthy (n=42). Ticagrelor (test drug) vs. Ticagrelor (reference drug) was evaluated on Peak plasma concentration (Cmax), area under the plasma concentration time curve (AUCT), and time to maximum drug concentration (Tmax). A single dose of the test ticagrelor formulation was bioequivalent to the reference product in healthy Indian adult males, with 90% CIs for AUCT and Cmax within the 80%-125% range.
Synapse has enriched 10 related papers. Consider them for comparative context: